RESUMO
Twenty patients who developed nosocomial Gram-negative bacteraemias in the medical or surgical intensive care units were treated with pefloxacin. All organisms were susceptible to pefloxacin and had not responded to previous antimicrobial therapy. The bacteraemias were eradicated in 16 of the 20 patients, all of whom tolerated the therapy without adverse effects.
Assuntos
Infecção Hospitalar/tratamento farmacológico , Pefloxacina/uso terapêutico , Sepse/tratamento farmacológico , Administração Oral , Adulto , Idoso , Resistência Microbiana a Medicamentos , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Pefloxacina/administração & dosagem , Pneumonia/complicações , Infecções por Pseudomonas/complicações , Infecções por Pseudomonas/tratamento farmacológico , Sepse/complicaçõesRESUMO
The subjects were adult hospitalized patients, 12 with pneumonia and eight with acute bronchitis. The patients with pneumonia received 500 mg of cefuroxime orally twice daily and the patients with bronchitis received 250 mg twice daily. Treatment lasted for ten days in responsive patients. The pathogens identified in the patients' sputum were Streptococcus pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae, Enterobacter aerogenes, Staphylococcus aureus, or Branhamella catarrhalis. Clinical and bacteriologic cures were achieved in 11 of the 12 patients with pneumonia and in seven of the eight patients with bronchitis. It is concluded that cefuroxime axetil is safe and effective in the treatment of community-acquired pneumonia or acute bronchitis.
